+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Carbapenem-Based Antibiotics Market - Global Forecast 2026-2032- Product Image
Carbapenem-Based Antibiotics Market - Global Forecast 2026-2032- Product Image
Sale

Carbapenem-Based Antibiotics Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6153947
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Carbapenem-Based Antibiotics Market is projected to reach USD 1.39 Billion in 2026. It is expected to continue growing at a CAGR of 5.86%, reaching USD 1.95 Billion by 2032.

Carbapenem-Based Antibiotics: Executive Summary and Strategic Context

Carbapenem-based antibiotics are broad-spectrum beta-lactam medicines used primarily for serious bacterial infections, including infections caused by organisms resistant to several other antibiotic classes. Their clinical role is shaped by hospital stewardship, microbiology capacity, infection-prevention practices, regulatory oversight, and the need to preserve effectiveness against multidrug-resistant pathogens. This summary focuses on evidence-based structural drivers, regional differences, and strategic priorities without presenting market estimates, forecasts, market shares, or company-specific analysis.

Resistance, Stewardship, and Hospital Practice Are Reshaping Use

The landscape is being transformed by antimicrobial resistance, tighter stewardship requirements, and greater emphasis on targeted therapy. Carbapenems are increasingly reserved for situations supported by local resistance data, clinical severity, or susceptibility testing, while diagnostic laboratories and hospital protocols influence whether treatment is started empirically and how quickly it is narrowed. Infection prevention, vaccination, sanitation, surveillance, and appropriate prescribing remain essential because unnecessary exposure can select for carbapenem-resistant organisms. Access and quality challenges also differ substantially between health systems, affecting availability, administration, monitoring, and continuity of care.

Artificial Intelligence Strengthens Surveillance, Diagnostics, and Stewardship

Artificial intelligence can support the carbapenem ecosystem by identifying resistance patterns, integrating laboratory and electronic health-record data, improving alerts for high-risk patients, and helping stewardship teams review prescribing at scale. Machine-learning tools may also assist with antimicrobial susceptibility interpretation, outbreak detection, dose optimization, and prioritization of microbiology workflows. Their value depends on representative datasets, validated clinical performance, interoperability, cybersecurity, and human oversight. AI should augment infectious-disease specialists and pharmacists rather than replace clinical judgment, particularly when evidence is incomplete or resistance mechanisms vary across settings.

Regional Differences Reflect Resistance Burden, Health-System Capacity, and Access

North America combines advanced diagnostics and stewardship infrastructure with persistent concerns about healthcare-associated resistance and uneven access across institutions. Europe places strong emphasis on surveillance, prudent prescribing, infection prevention, and coordinated public-health action. Asia-Pacific includes highly diverse regulatory, clinical, and laboratory environments, with major variation in antimicrobial access and resistance monitoring. Latin America faces heterogeneous stewardship capacity, constrained diagnostics in some settings, and substantial differences between public and private care. The Middle East is influenced by healthcare-associated transmission, international travel, referral networks, and varying laboratory capability. Africa requires expanded microbiology, reliable medicine supply, infection-prevention resources, and context-appropriate stewardship to address substantial gaps in surveillance and access.

Economic and Institutional Groups Show Distinct Policy Priorities

ASEAN countries must balance growing healthcare demand with uneven laboratory capacity, cross-border transmission risks, and variable antimicrobial regulation. BRICS members encompass large and diverse populations, making surveillance coordination, manufacturing quality, and equitable access important priorities. The European Union benefits from shared public-health coordination while retaining differences in national reimbursement, procurement, and clinical practice. G7 systems generally have stronger stewardship, regulatory, and diagnostic infrastructures but still face resistant hospital pathogens and pressure to sustain innovation. GCC countries are shaped by centralized procurement in some settings, high international mobility, and the need for coordinated infection control. NATO members span varied health systems, yet interoperability, preparedness, and protection against healthcare-associated threats support common surveillance and response objectives.

Country Contexts Vary Across Regulation, Diagnostics, and Clinical Practice

Australia emphasizes stewardship, national surveillance, and coordinated hospital practice. Brazil combines substantial clinical need with regional variation in laboratory access and infection-control capacity. Canada relies on stewardship and public-health coordination across geographically dispersed systems. China continues to strengthen prescribing controls, diagnostics, and resistance surveillance across a large and heterogeneous health sector. France, Germany, Italy, and Spain operate within European antimicrobial-resistance priorities while differing in procurement, hospital organization, and implementation. India faces a complex combination of high infectious-disease burden, uneven diagnostics, and the need for stronger stewardship and quality assurance. Japan and South Korea have advanced healthcare infrastructures but continue to monitor resistant organisms and demographic pressures. Mexico must address variation between healthcare sectors and regions. Russia’s priorities include surveillance, laboratory strengthening, and consistent clinical governance. The United Kingdom emphasizes national guidance, stewardship, surveillance, and infection prevention. The United States combines extensive diagnostic and stewardship capabilities with ongoing concern about resistant healthcare-associated infections.

Industry Leaders Should Link Access, Stewardship, Diagnostics, and Evidence

Leaders should align product strategy and clinical support with antimicrobial-stewardship principles rather than encouraging indiscriminate use. Priorities include investing in rapid and reliable susceptibility testing, supporting independent resistance surveillance, strengthening supply-chain quality and continuity, and developing educational programs for prescribers, pharmacists, and laboratory teams. Organizations should use transparent evidence standards for any AI-enabled tool, monitor outcomes and resistance signals after implementation, and design access initiatives for settings with limited diagnostics. Cross-sector collaboration with hospitals, public-health agencies, regulators, and academic partners can improve responsible use while addressing unmet needs in infection prevention and treatment.

Methodology: Evidence-Based Synthesis of Clinical, Policy, and Health-System Drivers

This executive summary uses a structured qualitative synthesis of established evidence domains relevant to carbapenem-based antibiotics: antimicrobial-resistance surveillance, clinical stewardship guidance, infection-prevention practice, diagnostic capability, regulatory and procurement conditions, and health-system access. Findings are organized across the requested regions, economic and political groups, and countries to identify recurring drivers and material differences. The approach intentionally excludes market estimates, forecasts, market shares, and company-specific claims. Interpretations should be updated as surveillance definitions, treatment guidelines, resistance patterns, and regulatory policies evolve.

Responsible Use and Resilient Systems Define the Market’s Strategic Direction

The central challenge is to preserve carbapenem effectiveness while ensuring timely treatment for patients with severe or resistant infections. Progress depends on integrating diagnostics, stewardship, infection prevention, surveillance, reliable supply, and equitable clinical access. Regional and country differences mean that implementation must be adapted to local resistance patterns and health-system capacity. Organizations that combine evidence-based clinical practice with strong data governance and accountable innovation will be better positioned to support patient outcomes and public-health resilience.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Carbapenem-Based Antibiotics Market, by Form
7.1. Introduction
7.2. Powder For Injection
7.3. Pre-Filled Syringe
8. Carbapenem-Based Antibiotics Market, by Product Status
8.1. Introduction
8.2. Branded
8.3. Generic
9. Carbapenem-Based Antibiotics Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.2.1. Private Hospital Pharmacy
9.2.2. Public Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Carbapenem-Based Antibiotics Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Clinics
10.4. Hospitals
10.4.1. Private Hospitals
10.4.2. Public Hospitals
11. Carbapenem-Based Antibiotics Market, by Type
11.1. Introduction
11.2. Doripenem
11.3. Ertapenem
11.4. Imipenem
11.5. Meropenem
12. Carbapenem-Based Antibiotics Market, by Application
12.1. Introduction
12.2. Bacterial Meningitis
12.3. Complicated Intra-Abdominal Infections
12.3.1. Adult
12.3.2. Pediatric
12.4. Complicated Urinary Tract Infections
12.4.1. Adult
12.4.2. Pediatric
12.5. Hospital-Acquired Pneumonia
12.5.1. ICU Patients
12.5.2. Non-ICU Patients
12.6. Skin And Soft Tissue Infections
12.7. Ventilator-Associated Pneumonia
12.7.1. ICU Patients
12.7.2. Non-ICU Patients
13. Carbapenem-Based Antibiotics Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Carbapenem-Based Antibiotics Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Carbapenem-Based Antibiotics Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AstraZeneca PLC
17.2. Cipla Ltd.
17.3. Dr. Reddy’s Laboratories Ltd.
17.4. Eli Lilly and Company
17.5. Fresenius Kabi AG
17.6. Fresenius Kabi LLC
17.7. GlaxoSmithKline plc
17.8. Hikma Pharmaceuticals PLC
17.9. Johnson & Johnson
17.10. Merck & Co., Inc.
17.11. Pfizer Inc.
17.12. Sandoz International GmbH
17.13. Sandoz International GmbH
17.14. Shionogi & Co., Ltd.
17.15. Sumitomo Dainippon Pharma Co. Ltd.
17.16. Teva Pharmaceutical Industries Ltd.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Carbapenem-Based Antibiotics Market, Years Considered for the Study
FIGURE 2. Global Carbapenem-Based Antibiotics Market, Research Design
FIGURE 3. Global Carbapenem-Based Antibiotics Market, Research Framework
FIGURE 4. Global Carbapenem-Based Antibiotics Market, Data Triangulation
FIGURE 5. Global Carbapenem-Based Antibiotics Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Carbapenem-Based Antibiotics Market Size, by Form, 2025 vs 2032 (%)
FIGURE 7. Global Carbapenem-Based Antibiotics Market Size, by Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Carbapenem-Based Antibiotics Market Size, by Product Status, 2025 vs 2032 (%)
FIGURE 9. Global Carbapenem-Based Antibiotics Market Size, by Product Status, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Carbapenem-Based Antibiotics Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 11. Global Carbapenem-Based Antibiotics Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Carbapenem-Based Antibiotics Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Carbapenem-Based Antibiotics Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Carbapenem-Based Antibiotics Market Size, by Type, 2025 vs 2032 (%)
FIGURE 15. Global Carbapenem-Based Antibiotics Market Size, by Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Carbapenem-Based Antibiotics Market Size, by Application, 2025 vs 2032 (%)
FIGURE 17. Global Carbapenem-Based Antibiotics Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Carbapenem-Based Antibiotics Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Carbapenem-Based Antibiotics Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Carbapenem-Based Antibiotics Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Carbapenem-Based Antibiotics Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Carbapenem-Based Antibiotics Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Carbapenem-Based Antibiotics Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Carbapenem-Based Antibiotics Market Segmentation & Coverage
TABLE 2. Global Carbapenem-Based Antibiotics Market Size, 2017-2032 (USD Million)
TABLE 3. Global Carbapenem-Based Antibiotics Market Size, by Form, 2017-2032 (USD Million)
TABLE 4. Global Powder For Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Powder For Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Powder For Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Pre-Filled Syringe Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Pre-Filled Syringe Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Pre-Filled Syringe Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Carbapenem-Based Antibiotics Market Size, by Product Status, 2017-2032 (USD Million)
TABLE 11. Global Branded Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Branded Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Branded Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Generic Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Generic Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Generic Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Carbapenem-Based Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 18. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 19. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 20. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 21. Global Private Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Private Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Private Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Public Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Public Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Public Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Carbapenem-Based Antibiotics Market Size, by End User, 2017-2032 (USD Million)
TABLE 34. Global Ambulatory Surgical Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Ambulatory Surgical Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Ambulatory Surgical Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Private Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Private Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Private Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Public Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Public Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Public Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Carbapenem-Based Antibiotics Market Size, by Type, 2017-2032 (USD Million)
TABLE 50. Global Doripenem Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Doripenem Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Doripenem Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Ertapenem Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Ertapenem Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Ertapenem Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Imipenem Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Imipenem Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Imipenem Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Meropenem Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Meropenem Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Meropenem Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Carbapenem-Based Antibiotics Market Size, by Application, 2017-2032 (USD Million)
TABLE 63. Global Bacterial Meningitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Bacterial Meningitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Bacterial Meningitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Complicated Intra-Abdominal Infections Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Complicated Intra-Abdominal Infections Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Complicated Intra-Abdominal Infections Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Complicated Urinary Tract Infections Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Complicated Urinary Tract Infections Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Complicated Urinary Tract Infections Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Hospital-Acquired Pneumonia Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Hospital-Acquired Pneumonia Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Hospital-Acquired Pneumonia Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global ICU Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global ICU Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global ICU Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global Non-ICU Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Non-ICU Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Non-ICU Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global Skin And Soft Tissue Infections Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global Skin And Soft Tissue Infections Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global Skin And Soft Tissue Infections Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Ventilator-Associated Pneumonia Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Ventilator-Associated Pneumonia Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Ventilator-Associated Pneumonia Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global ICU Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Global ICU Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. Global ICU Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 102. Global Non-ICU Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Global Non-ICU Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. Global Non-ICU Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 105. Global Carbapenem-Based Antibiotics Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Asia-Pacific Carbapenem-Based Antibiotics Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Asia-Pacific Carbapenem-Based Antibiotics Market Size, by Form, 2017-2032 (USD Million)
TABLE 108. Asia-Pacific Carbapenem-Based Antibiotics Market Size, by Product Status, 2017-2032 (USD Million)
TABLE 109. Asia-Pacific Carbapenem-Based Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 110. Asia-Pacific Carbapenem-Based Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 111. Asia-Pacific Carbapenem-Based Antibiotics Market Size, by End User, 2017-2032 (USD Million)
TABLE 112. Asia-Pacific Carbapenem-Based Antibiotics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 113. Asia-Pacific Carbapenem-Based Antibiotics Market Size, by Type, 2017-2032 (USD Million)
TABLE 114. Asia-Pacific Carbapenem-Based Antibiotics Market Size, by Application, 2017-2032 (USD Million)
TABLE 115. Asia-Pacific Carbapenem-Based Antibiotics Market Size, by Complicated Intra-Abdominal Infections, 2017-2032 (USD Million)
TABLE 116. Asia-Pacific Carbapenem-Based Antibiotics Market Size, by Complicated Urinary Tract Infections, 2017-2032 (USD Million)
TABLE 117. Asia-Pacific Carbapenem-Based Antibiotics Market Size, by Hospital-Acquired Pneumonia, 2017-2032 (USD Million)
TABLE 118. Asia-Pacific Carbapenem-Based Antibiotics Market Size, by Ventilator-Associated Pneumonia, 2017-2032 (USD Million)
TABLE 119. North America Carbapenem-Based Antibiotics Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. North America Carbapenem-Based Antibiotics Market Size, by Form, 2017-2032 (USD Million)
TABLE 121. North America Carbapenem-Based Antibiotics Market Size, by Product Status, 2017-2032 (USD Million)
TABLE 122. North America Carbapenem-Based Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 123. North America Carbapenem-Based Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 124. North America Carbapenem-Based Antibiotics Market Size, by End User, 2017-2032 (USD Million)
TABLE 125. North America Carbapenem-Based Antibiotics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 126. North America Carbapenem-Based Antibiotics Market Size, by Type, 2017-2032 (USD Million)
TABLE 127. North America Carbapenem-Based Antibiotics Market Size, by Application, 2017-2032 (USD Million)
TABLE 128. North America Carbapenem-Based Antibiotics Market Size, by Complicated Intra-Abdominal Infections, 2017-2032 (USD Million)
TABLE 129. North America Carbapenem-Based Antibiotics Market Size, by Complicated Urinary Tract Infections, 2017-2032 (USD Million)
TABLE 130. North America Carbapenem-Based Antibiotics Market Size, by Hospital-Acquired Pneumonia, 2017-2032 (USD Million)
TABLE 131. North America Carbapenem-Based Antibiotics Market Size, by Ventilator-Associated Pneumonia, 2017-2032 (USD Million)
TABLE 132. Latin America Carbapenem-Based Antibiotics Market Size, by Region, 2017-2032 (USD Million)
TABLE 133. Latin America Carbapenem-Based Antibiotics Market Size, by Form, 2017-2032 (USD Million)
TABLE 134. Latin America Carbapenem-Based Antibiotics Market Size, by Product Status, 2017-2032 (USD Million)
TABLE 135. Latin America Carbapenem-Based Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 136. Latin America Carbapenem-Based Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 137. Latin America Carbapenem-Based Antibiotics Market Size, by End User, 2017-2032 (USD Million)
TABLE 138. Latin America Carbapenem-Based Antibiotics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 139. Latin America Carbapenem-Based Antibiotics Market Size, by Type, 2017-2032 (USD Million)
TABLE 140. Latin America Carbapenem-Based Antibiotics Market Size, by Application, 2017-2032 (USD Million)
TABLE 141. Latin America Carbapenem-Based Antibiotics Market Size, by Complicated Intra-Abdominal Infections, 2017-2032 (USD Million)
TABLE 142. Latin America Carbapenem-Based Antibiotics Market Size, by Complicated Urinary Tract Infections, 2017-2032 (USD Million)
TABLE 143. Latin America Carbapenem-Based Antibiotics Market Size, by Hospital-Acquired Pneumonia, 2017-2032 (USD Million)
TABLE 144. Latin America Carbapenem-Based Antibiotics Market Size, by Ventilator-Associated Pneumonia, 2017-2032 (USD Million)
TABLE 145. Europe Carbapenem-Based Antibiotics Market Size, by Region, 2017-2032 (USD Million)
TABLE 146. Europe Carbapenem-Based Antibiotics Market Size, by Form, 2017-2032 (USD Million)
TABLE 147. Europe Carbapenem-Based Antibiotics Market Size, by Product Status, 2017-2032 (USD Million)
TABLE 148. Europe Carbapenem-Based Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 149. Europe Carbapenem-Based Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 150. Europe Carbapenem-Based Antibiotics Market Size, by End User, 2017-2032 (USD Million)
TABLE 151. Europe Carbapenem-Based Antibiotics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 152. Europe Carbapenem-Based Antibiotics Market Size, by Type, 2017-2032 (USD Million)
TABLE 153. Europe Carbapenem-Based Antibiotics Market Size, by Application, 2017-2032 (USD Million)
TABLE 154. Europe Carbapenem-Based Antibiotics Market Size, by Complicated Intra-Abdominal Infections, 2017-2032 (USD Million)
TABLE 155. Europe Carbapenem-Based Antibiotics Market Size, by Complicated Urinary Tract Infections, 2017-2032 (USD Million)
TABLE 156. Europe Carbapenem-Based Antibiotics Market Size, by Hospital-Acquired Pneumonia, 2017-2032 (USD Million)
TABLE 157. Europe Carbapenem-Based Antibiotics Market Size, by Ventilator-Associated Pneumonia, 2017-2032 (USD Million)
TABLE 158. Middle East Carbapenem-Based Antibiotics Market Size, by Region, 2017-2032 (USD Million)
TABLE 159. Middle East Carbapenem-Based Antibiotics Market Size, by Form, 2017-2032 (USD Million)
TABLE 160. Middle East Carbapenem-Based Antibiotics Market Size, by Product Status, 2017-2032 (USD Million)
TABLE 161. Middle East Carbapenem-Based Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 162. Middle East Carbapenem-Based Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 163. Middle East Carbapenem-Based Antibiotics Market Size, by End User, 2017-2032 (USD Million)
TABLE 164. Middle East Carbapenem-Based Antibiotics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 165. Middle East Carbapenem-Based Antibiotics Market Size, by Type, 2017-2032 (USD Million)
TABLE 166. Middle East Carbapenem-Based Antibiotics Market Size, by Application, 2017-2032 (USD Million)
TABLE 167. Middle East Carbapenem-Based Antibiotics Market Size, by Complicated Intra-Abdominal Infections, 2017-2032 (USD Million)
TABLE 168. Middle East Carbapenem-Based Antibiotics Market Size, by Complicated Urinary Tract Infections, 2017-2032 (USD Million)
TABLE 169. Middle East Carbapenem-Based Antibiotics Market Size, by Hospital-Acquired Pneumonia, 2017-2032 (USD Million)
TABLE 170. Middle East Carbapenem-Based Antibiotics Market Size, by Ventilator-Associated Pneumonia, 2017-2032 (USD Million)
TABLE 171. Africa Carbapenem-Based Antibiotics Market Size, by Region, 2017-2032 (USD Million)
TABLE 172. Africa Carbapenem-Based Antibiotics Market Size, by Form, 2017-2032 (USD Million)
TABLE 173. Africa Carbapenem-Based Antibiotics Market Size, by Product Status, 2017-2032 (USD Million)
TABLE 174. Africa Carbapenem-Based Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 175. Africa Carbapenem-Based Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 176. Africa Carbapenem-Based Antibiotics Market Size, by End User, 2017-2032 (USD Million)
TABLE 177. Africa Carbapenem-Based Antibiotics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 178. Africa Carbapenem-Based Antibiotics Market Size, by Type, 2017-2032 (USD Million)
TABLE 179. Africa Carbapenem-Based Antibiotics Market Size, by Application, 2017-2032 (USD Million)
TABLE 180. Africa Carbapenem-Based Antibiotics Market Size, by Complicated Intra-Abdominal Infections, 2017-2032 (USD Million)
TABLE 181. Africa Carbapenem-Based Antibiotics Market Size, by Complicated Urinary Tract Infections, 2017-2032 (USD Million)
TABLE 182. Africa Carbapenem-Based Antibiotics Market Size, by Hospital-Acquired Pneumonia, 2017-2032 (USD Million)
TABLE 183. Africa Carbapenem-Based Antibiotics Market Size, by Ventilator-Associated Pneumonia, 2017-2032 (USD Million)
TABLE 184. Global Carbapenem-Based Antibiotics Market Size, by Group, 2017-2032 (USD Million)
TABLE 185. ASEAN Carbapenem-Based Antibiotics Market Size, by Group, 2017-2032 (USD Million)
TABLE 186. ASEAN Carbapenem-Based Antibiotics Market Size, by Form, 2017-2032 (USD Million)
TABLE 187. ASEAN Carbapenem-Based Antibiotics Market Size, by Product Status, 2017-2032 (USD Million)
TABLE 188. ASEAN Carbapenem-Based Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 189. ASEAN Carbapenem-Based Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 190. ASEAN Carbapenem-Based Antibiotics Market Size, by End User, 2017-2032 (USD Million)
TABLE 191. ASEAN Carbapenem-Based Antibiotics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 192. ASEAN Carbapenem-Based Antibiotics Market Size, by Type, 2017-2032 (USD Million)
TABLE 193. ASEAN Carbapenem-Based Antibiotics Market Size, by Application, 2017-2032 (USD Million)
TABLE 194. ASEAN Carbapenem-Based Antibiotics Market Size, by Complicated Intra-Abdominal Infections, 2017-2032 (USD Million)
TABLE 195. ASEAN Carbapenem-Based Antibiotics Market Size, by Complicated Urinary Tract Infections, 2017-2032 (USD Million)
TABLE 196. ASEAN Carbapenem-Based Antibiotics Market Size, by Hospital-Acquired Pneumonia, 2017-2032 (USD Million)
TABLE 197. ASEAN Carbapenem-Based Antibiotics Market Size, by Ventilator-Associated Pneumonia, 2017-2032 (USD Million)
TABLE 198. GCC Carbapenem-Based Antibiotics Market Size, by Group, 2017-2032 (USD Million)
TABLE 199. GCC Carbapenem-Based Antibiotics Market Size, by Form, 2017-2032 (USD Million)
TABLE 200. GCC Carbapenem-Based Antibiotics Market Size, by Product Status, 2017-2032 (USD Million)
TABLE 201. GCC Carbapenem-Based Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 202. GCC Carbapenem-Based Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 203. GCC Carbapenem-Based Antibiotics Market Size, by End User, 2017-2032 (USD Million)
TABLE 204. GCC Carbapenem-Based Antibiotics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 205. GCC Carbapenem-Based Antibiotics Market Size, by Type, 2017-2032 (USD Million)
TABLE 206. GCC Carbapenem-Based Antibiotics Market Size, by Application, 2017-2032 (USD Million)
TABLE 207. GCC Carbapenem-Based Antibiotics Market Size, by Complicated Intra-Abdominal Infections, 2017-2032 (USD Million)
TABLE 208. GCC Carbapenem-Based Antibiotics Market Size, by Complicated Urinary Tract Infections, 2017-2032 (USD Million)
TABLE 209. GCC Carbapenem-Based Antibiotics Market Size, by Hospital-Acquired Pneumonia, 2017-2032 (USD Million)
TABLE 210. GCC Carbapenem-Based Antibiotics Market Size, by Ventilator-Associated Pneumonia, 2017-2032 (USD Million)
TABLE 211. European Union Carbapenem-Based Antibiotics Market Size, by Group, 2017-2032 (USD Million)
TABLE 212. European Union Carbapenem-Based Antibiotics Market Size, by Form, 2017-2032 (USD Million)
TABLE 213. European Union Carbapenem-Based Antibiotics Market Size, by Product Status, 2017-2032 (USD Million)
TABLE 214. European Union Carbapenem-Based Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 215. European Union Carbapenem-Based Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 216. European Union Carbapenem-Based Antibiotics Market Size, by End User, 2017-2032 (USD Million)
TABLE 217. European Union Carbapenem-Based Antibiotics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 218. European Union Carbapenem-Based Antibiotics Market Size, by Type, 2017-2032 (USD Million)
TABLE 219. European Union Carbapenem-Based Antibiotics Market Size, by Application, 2017-2032 (USD Million)
TABLE 220. European Union Carbapenem-Based Antibiotics Market Size, by Complicated Intra-Abdominal Infections, 2017-2032 (USD Million)
TABLE 221. European Union Carbapenem-Based Antibiotics Market Size, by Complicated Urinary Tract Infections, 2017-2032 (USD Million)
TABLE 222. European Union Carbapenem-Based Antibiotics Market Size, by Hospital-Acquired Pneumonia, 2017-2032 (USD Million)
TABLE 223. European Union Carbapenem-Based Antibiotics Market Size, by Ventilator-Associated Pneumonia, 2017-2032 (USD Million)
TABLE 224. BRICS Carbapenem-Based Antibiotics Market Size, by Group, 2017-2032 (USD Million)
TABLE 225. BRICS Carbapenem-Based Antibiotics Market Size, by Form, 2017-2032 (USD Million)
TABLE 226. BRICS Carbapenem-Based Antibiotics Market Size, by Product Status, 2017-2032 (USD Million)
TABLE 227. BRICS Carbapenem-Based Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 228. BRICS Carbapenem-Based Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 229. BRICS Carbapenem-Based Antibiotics Market Size, by End User, 2017-2032 (USD Million)
TABLE 230. BRICS Carbapenem-Based Antibiotics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 231. BRICS Carbapenem-Based Antibiotics Market Size, by Type, 2017-2032 (USD Million)
TABLE 232. BRICS Carbapenem-Based Antibiotics Market Size, by Application, 2017-2032 (USD Million)
TABLE 233. BRICS Carbapenem-Based Antibiotics Market Size, by Complicated Intra-Abdominal Infections, 2017-2032 (USD Million)
TABLE 234. BRICS Carbapenem-Based Antibiotics Market Size, by Complicated Urinary Tract Infections, 2017-2032 (USD Million)
TABLE 235. BRICS Carbapenem-Based Antibiotics Market Size, by Hospital-Acquired Pneumonia, 2017-2032 (USD Million)
TABLE 236. BRICS Carbapenem-Based Antibiotics Market Size, by Ventilator-Associated Pneumonia, 2017-2032 (USD Million)
TABLE 237. G7 Carbapenem-Based Antibiotics Market Size, by Group, 2017-2032 (USD Million)
TABLE 238. G7 Carbapenem-Based Antibiotics Market Size, by Form, 2017-2032 (USD Million)
TABLE 239. G7 Carbapenem-Based Antibiotics Market Size, by Product Status, 2017-2032 (USD Million)
TABLE 240. G7 Carbapenem-Based Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 241. G7 Carbapenem-Based Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 242. G7 Carbapenem-Based Antibiotics Market Size, by End User, 2017-2032 (USD Million)
TABLE 243. G7 Carbapenem-Based Antibiotics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 244. G7 Carbapenem-Based Antibiotics Market Size, by Type, 2017-2032 (USD Million)
TABLE 245. G7 Carbapenem-Based Antibiotics Market Size, by Application, 2017-2032 (USD Million)
TABLE 246. G7 Carbapenem-Based Antibiotics Market Size, by Complicated Intra-Abdominal Infections, 2017-2032 (USD Million)
TABLE 247. G7 Carbapenem-Based Antibiotics Market Size, by Complicated Urinary Tract Infections, 2017-2032 (USD Million)
TABLE 248. G7 Carbapenem-Based Antibiotics Market Size, by Hospital-Acquired Pneumonia, 2017-2032 (USD Million)
TABLE 249. G7 Carbapenem-Based Antibiotics Market Size, by Ventilator-Associated Pneumonia, 2017-2032 (USD Million)
TABLE 250. NATO Carbapenem-Based Antibiotics Market Size, by Group, 2017-2032 (USD Million)
TABLE 251. NATO Carbapenem-Based Antibiotics Market Size, by Form, 2017-2032 (USD Million)
TABLE 252. NATO Carbapenem-Based Antibiotics Market Size, by Product Status, 2017-2032 (USD Million)
TABLE 253. NATO Carbapenem-Based Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 254. NATO Carbapenem-Based Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 255. NATO Carbapenem-Based Antibiotics Market Size, by End User, 2017-2032 (USD Million)
TABLE 256. NATO Carbapenem-Based Antibiotics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 257. NATO Carbapenem-Based Antibiotics Market Size, by Type, 2017-2032 (USD Million)
TABLE 258. NATO Carbapenem-Based Antibiotics Market Size, by Application, 2017-2032 (USD Million)
TABLE 259. NATO Carbapenem-Based Antibiotics Market Size, by Complicated Intra-Abdominal Infections, 2017-2032 (USD Million)
TABLE 260. NATO Carbapenem-Based Antibiotics Market Size, by Complicated Urinary Tract Infections, 2017-2032 (USD Million)
TABLE 261. NATO Carbapenem-Based Antibiotics Market Size, by Hospital-Acquired Pneumonia, 2017-2032 (USD Million)
TABLE 262. NATO Carbapenem-Based Antibiotics Market Size, by Ventilator-Associated Pneumonia, 2017-2032 (USD Million)
TABLE 263. Global Carbapenem-Based Antibiotics Market Size, by Country, 2017-2032 (USD Million)
TABLE 264. United States Carbapenem-Based Antibiotics Market Size, 2017-2032 (USD Million)
TABLE 265. United States Carbapenem-Based Antibiotics Market Size, by Form, 2017-2032 (USD Million)
TABLE 266. United States Carbapenem-Based Antibiotics Market Size, by Product Status, 2017-2032 (USD Million)
TABLE 267. United States Carbapenem-Based Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 268. United States Carbapenem-Based Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 269. United States Carbapenem-Based Antibiotics Market Size, by End User, 2017-2032 (USD Million)
TABLE 270. United States Carbapenem-Based Antibiotics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 271. United States Carbapenem-Based Antibiotics Market Size, by Type, 2017-2032 (USD Million)
TABLE 272. United States Carbapenem-Based Antibiotics Market Size, by Application, 2017-2032 (USD Million)
TABLE 273. United States Carbapenem-Based Antibiotics Market Size, by Complicated Intra-Abdominal Infections, 2017-2032 (USD Million)
TABLE 274. United States Carbapenem-Based Antibiotics Market Size, by Complicated Urinary Tract Infections, 2017-2032 (USD Million)
TABLE 275. United States Carbapenem-Based Antibiotics Market Size, by Hospital-Acquired Pneumonia, 2017-2032 (USD Million)
TABLE 276. United States Carbapenem-Based Antibiotics Market Size, by Ventilator-Associated Pneumonia, 2017-2032 (USD Million)
TABLE 277. Canada Carbapenem-Based Antibiotics Market Size, 2017-2032 (USD Million)
TABLE 278. Canada Carbapenem-Based Antibiotics Market Size, by Form, 2017-2032 (USD Million)
TABLE 279. Canada Carbapenem-Based Antibiotics Market Size, by Product Status, 2017-2032 (USD Million)
TABLE 280. Canada Carbapenem-Based Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 281. Canada Carbapenem-Based Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 282. Canada Carbapenem-Based Antibiotics Market Size, by End User, 2017-2032 (USD Million)
TABLE 283. Canada Carbapenem-Based Antibiotics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 284. Canada Carbapenem-Based Antibiotics Market Size, by Type, 2017-2032 (USD Million)
TABLE 285. Canada Carbapenem-Based Antibiotics Market Size, by Application, 2017-2032 (USD Million)
TABLE 286. Canada Carbapenem-Based Antibiotics Market Size, by Complicated Intra-Abdominal Infections, 2017-2032 (USD Million)
TABLE 287. Canada Carbapenem-Based Antibiotics Market Size, by Complicated Urinary Tract Infections, 2017-2032 (USD Million)
TABLE 288. Canada Carbapenem-Based Antibiotics Market Size, by Hospital-Acquired Pneumonia, 2017-2032 (USD Million)
TABLE 289. Canada Carbapenem-Based Antibiotics Market Size, by Ventilator-Associated Pneumonia, 2017-2032 (USD Million)
TABLE 290. Mexico Carbapenem-Based Antibiotics Market Size, 2017-2032 (USD Million)
TABLE 291. Mexico Carbapenem-Based Antibiotics Market Size, by Form, 2017-2032 (USD Million)
TABLE 292. Mexico Carbapenem-Based Antibiotics Market Size, by Product Status, 2017-2032 (USD Million)
TABLE 293. Mexico Carbapenem-Based Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 294. Mexico Carbapenem-Based Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 295. Mexico Carbapenem-Based Antibiotics Market Size, by End User, 2017-2032 (USD Million)
TABLE 296. Mexico Carbapenem-Based Antibiotics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 297. Mexico Carbapenem-Based Antibiotics Market Size, by Type, 2017-2032 (USD Million)
TABLE 298. Mexico Carbapenem-Based Antibiotics Market Size, by Application, 2017-2032 (USD Million)
TABLE 299. Mexico Carbapenem-Based Antibiotics Market Size, by Complicated Intra-Abdominal Infections, 2017-2032 (USD Million)
TABLE 300. Mexico Carbapenem-Based Antibiotics Market Size, by Complicated Urinary Tract Infections, 2017-2032 (USD Million)
TABLE 301. Mexico Carbapenem-Based Antibiotics Market Size, by Hospital-Acquired Pneumonia, 2017-2032 (USD Million)
TABLE 302. Mexico Carbapenem-Based Antibiotics Market Size, by Ventilator-Associated Pneumonia, 2017-2032 (USD Million)
TABLE 303. Brazil Carbapenem-Based Antibiotics Market Size, 2017-2032 (USD Million)
TABLE 304. Brazil Carbapenem-Based Antibiotics Market Size, by Form, 2017-2032 (USD Million)
TABLE 305. Brazil Carbapenem-Based Antibiotics Market Size, by Product Status, 2017-2032 (USD Million)
TABLE 306. Brazil Carbapenem-Based Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 307. Brazil Carbapenem-Based Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 308. Brazil Carbapenem-Based Antibiotics Market Size, by End User, 2017-2032 (USD Million)
TABLE 309. Brazil Carbapenem-Based Antibiotics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 310. Brazil Carbapenem-Based Antibiotics Market Size, by Type, 2017-2032 (USD Million)
TABLE 311. Brazil Carbapenem-Based Antibiotics Market Size, by Application, 2017-2032 (USD Million)
TABLE 312. Brazil Carbapenem-Based Antibiotics Market Size, by Complicated Intra-Abdominal Infections, 2017-2032 (USD Million)
TABLE 313. Brazil Carbapenem-Based Antibiotics Market Size, by Complicated Urinary Tract Infections, 2017-2032 (USD Million)
TABLE 314. Brazil Carbapenem-Based Antibiotics Market Size, by Hospital-Acquired Pneumonia, 2017-2032 (USD Million)
TABLE 315. Brazil Carbapenem-Based Antibiotics Market Size, by Ventilator-Associated Pneumonia, 2017-2032 (USD Million)
TABLE 316. United Kingdom Carbapenem-Based Antibiotics Market Size, 2017-2032 (USD Million)
TABLE 317. United Kingdom Carbapenem-Based Antibiotics Market Size, by Form, 2017-2032 (USD Million)
TABLE 318. United Kingdom Carbapenem-Based Antibiotics Market Size, by Product Status, 2017-2032 (USD Million)
TABLE 319. United Kingdom Carbapenem-Based Antibiotics Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 320. United Kingdom Carbapenem-Based Antibiotics Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 321. United Kingdom Carbapenem-Based Antibiotics Market Size, by End User, 2017-2032 (USD Million)
TABLE 322. United Kingdom Carbapenem-Based Antibiotics Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 323. United Kingdom Carbapenem-Based Antibiotics Market Size, by Type, 2017-2032 (USD Million)
TABLE 324. United Kingdom Carbapenem-Based Antibiotics Market Size, by Application, 2017-2032 (USD Million)
TABLE 325. United Kingdom Carbapenem-Based Antibiotics Market Size, by Complicated Intra-Abdominal Infections, 2017-2032 (USD Million)
TABLE 326. United Kingdom Carbapenem-Based Antibiotics Market Size, by Complicated Urinary Tract Infections, 2017-2032 (USD Million)
TABLE 327. United Kingdom Carbapenem-Based Antibiotics Market Size, by Hospital-Acquired Pneumonia, 2017-2032 (USD Million)
TABLE 328. United Kingdom Carbapene

Companies Mentioned

  • AstraZeneca PLC
  • Cipla Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Fresenius Kabi LLC
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sandoz International GmbH
  • Shionogi & Co., Ltd.
  • Sumitomo Dainippon Pharma Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.

Related Topics

Related Reports

4-AA for Carbapenem Antibiotic Market - Global Forecast 2026-2032 - Product Image

4-AA for Carbapenem Antibiotic Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Carbapenem-Based Antibiotics Market Report 2026 - Product Image

Carbapenem-Based Antibiotics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Carbapenem - Global Strategic Business Report - Product Image

Carbapenem - Global Strategic Business Report

  • Report
  • 383 Pages
  • Global
From
Carbapenem-Based Antibiotics Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Carbapenem-Based Antibiotics Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Carbapenem-Resistant Enterobacteriaceae Infection - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Carbapenem-Resistant Enterobacteriaceae Infection - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.